Efficacy and safety of the all-oral schedule of metronomic vinorelbine and capecitabine in locally advanced or metastatic breast cancer patients: The phase I-II VICTOR-1 study

International Journal of Breast Cancer

Volumn 2014, Issue 1, 2014, Pages

  Cazzaniga, M E ^a   Torri, V ^b   Villa, F ^a   Giuntini, N ^a   Riva, F ^a   Zeppellini, A ^a   Cortinovis, D ^a   Bidoli, P ^a  

^a Oncology Department   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTHRACYCLINE; CAPECITABINE; CLINDAMYCIN; EPIRUBICIN; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASTHENIA; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DISEASE FREE INTERVAL; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; DYSPNEA; ELECTROCORTICOGRAPHY; ERYSIPELAS; FEMALE; HAND FOOT SYNDROME; HEART FAILURE; HUMAN; HYPERTRANSAMINASEMIA; LABELING INDEX; LEUKOPENIA; LIVER METASTASIS; METRONOMIC CHEMOTHERAPY; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAUSEA; NEUROPATHY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; STOMACH PAIN; STOMATITIS; THROMBOCYTOPENIA; TOXICITY; VERY ELDERLY;

EID: 84907315246     PISSN: None     EISSN: 20903189     Source Type: Journal    
DOI: 10.1155/2014/769790     Document Type: Article

References (15)

1. Sawada M., Fujimoto-Ouchi K., Antitumour activity of combination therapy with CAPE plus VRB and CAPE plus gemcitabine in human tumour xenograft models. American Association for Cancer Research 2002 43 1088
2. Hess D., Thurlimann B., Pagani O., CAPE and VRB as I line treatment in elderly patients with metastatic breast cancer. Oncology 2008 73 3-4 228 237 2-s2.0-43049090899
3. Lorusso V., Cinieri S., Giampaglia M., Ciccarese M., Tinelli A., Chiuri V., Manca C., Silvestris N., Gasparini G., Colucci G., Intravenous versus oral vinorelbine plus capecitabine as second-line treatment in advanced breast cancer patients. A retrospective comparison of two consecutive phase II studies. Breast 2010 19 3 214 218 2-s2.0-77953359063 10.1016/j.breast.2010.01.015
4. Nolè F., Crivellari D., Mattioli R., Pinotti G., Foa P., Verri E., Fougeray R., Brandely M., Goldhirsch A., Phase II study of an all-oral combination of vinorelbine with capecitabine in patients with metastatic breast cancer. Cancer Chemotherapy and Pharmacology 2009 64 4 673 680 2-s2.0-68149168065 10.1007/s00280-008-0915-3
5. Tubiana-Mathieu N., Bougnoux P., Becquart D., Chan A., Conte P.-F., Majois F., Espie M., Morand M., Vaissiere N., Villanova G., All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International Phase II Trial. British Journal of Cancer 2009 101 2 232 237 2-s2.0-67650632393 10.1038/sj.bjc.6605156
6. Kerbel R. S., Kamen B. A., The anti-angiogenic basis of metronomic chemotherapy. Nature Reviews Cancer 2004 4 6 423 436 2-s2.0-2942615257 (Pubitemid 38745528)
7. Dellapasqua S., Bertolini F., Bagnardi V., Campagnoli E., Scarano E., Torrisi R., Shaked Y., Mancuso P., Goldhirsch A., Rocca A., Pietri E., Colleoni M., Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. Journal of Clinical Oncology 2008 26 30 4899 4905 2-s2.0-54449099774 10.1200/JCO.2008.17.4789
8. Briasoulis E., Pappas P., Puozzo C., Tolis C., Fountzilas G., Dafni U., Marselos M., Pavlidis N., Dose-ranging study of metronomic oral vinorelbine in patients with advanced refractory cancer. Clinical Cancer Research 2009 15 20 6454 6461 2-s2.0-70350212970 10.1158/1078-0432.CCR-09-0970
9. Saridaki Z., Malamos N., Kourakos P., A Phase I trial or oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer. Cancer Chemotherapy and Pharmacology 2012 69 1 35 42 10.1007/s00280-011-1663-3
10. Lorusso V., Spada M., Giampaglia M., Misino A., Calabrese R., Latorre A., Monticelli G., Guida M., Sambiasi D., Colucci G., Oral vinorelbine plus capecitabine (oral vincap) combination in patients with advanced breast cancer (ABC). A phase II study of the GOIM (Gruppo Oncologico dell'Italia Meridionale). Annals of Oncology 2006 17 supplement 7 vii15 vii17 2-s2.0-33745613545 10.1093/annonc/mdl942 (Pubitemid 43985171)
11. Nolè F., Catania C., Sanna G., Imadalou K., Munzone E., Adamoli L., Longerey B., Blanchot G., Goldhirsch A., Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer. Annals of Oncology 2006 17 2 322 329 2-s2.0-31544475481 10.1093/annonc/mdj058 (Pubitemid 43160124)
12. Finek J., Holubec L. Jr., Svoboda T., Sefrhansova L., Pavlikova I., Votavova M., Sediva M., Filip S., Kozevnikova R., Kormunda S., A phase II trial of oral vinorelbine and capecitabine in anthracycline pretreated patients with metastatic breast cancer. Anticancer Research 2009 29 2 667 670 2-s2.0-61449209114
13. Gampenrieder S. P., Bartsch R., Matzneller P., Pluschnig U., Dubsky P., Gnant M. X., Zielinski C. C., Steger G. G., Capecitabine and vinorelbine as an all-oral chemotherapy in HER2-negative locally advanced and metastatic breast cancer. Breast Care 2010 5 3 158 162 2-s2.0-77954500272 10.1159/000314214
14. Jones A., O'Brien M., Sommer H., Nowara E., Welt A., Pienkowski T., Rolski J., Pham M.-L., Perraud K., Trillet-Lenoir V., Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes. Cancer Chemotherapy and Pharmacology 2010 65 4 755 763 2-s2.0-75749084059 10.1007/s00280-009-1081-y
15. Hennessy B. T., Gauthier A. M., Michaud L. B., Hortobagyi G., Valero V., Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature. Annals of Oncology 2005 16 8 1289 1296 2-s2.0-23844449433 10.1093/annonc/mdi253 (Pubitemid 41158473)